NeuroSense Gross Profit from 2010 to 2024

NRSNW Stock

USD 0.25 0.01 4.17%

NeuroSense Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit NeuroSense Therapeutics Ltd makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

-97 K

Current Value

-92.2 K

Quarterly Volatility

37.2 K

Credit Downgrade

Yuan Drop

Covid

Check NeuroSense Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuroSense Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 186.9 K, Depreciation And Amortization of 101.8 K or Interest Expense of 379.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NeuroSense financial statements analysis is a perfect complement when working with NeuroSense Therapeutics Valuation or Volatility modules.

Check out the analysis of NeuroSense Therapeutics Correlation against competitors.

For more information on how to buy NeuroSense Stock please use our How to Invest in NeuroSense Therapeutics guide.

Latest NeuroSense Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of NeuroSense Therapeutics Ltd over the last few years. Gross profit is a required income statement account that reflects total revenue of NeuroSense Therapeutics Ltd minus its cost of goods sold. It is profit before NeuroSense Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. NeuroSense Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeuroSense Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

NeuroSense Gross Profit Regression Statistics

	Arithmetic Mean	(20,943)
	Coefficient Of Variation	(177.51)
	Mean Deviation	28,709
	Median	(3,000)
	Standard Deviation	37,177
	Sample Variance	1.4B
	Range	94K
	R-Value	(0.70)
	Mean Square Error	769.2M
	R-Squared	0.48
	Significance	0
	Slope	(5,779)
	Total Sum of Squares	19.4B

NeuroSense Gross Profit History

	2024	-92.2 K
	2023	-97 K
	2022	-89 K

Other Fundumenentals of NeuroSense Therapeutics

Gross Profit Margin

NeuroSense Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Short Term Debt
Total Assets		0.74	-0.95	-0.52	0.33	0.87	0.6	0.74	1.0	0.85	-0.25	0.24
Total Stockholder Equity	0.74		-0.77	0.15	-0.38	0.4	-0.09	1.0	0.75	0.98	0.46	-0.47
Net Debt	-0.95	-0.77		0.36	-0.19	-0.81	-0.49	-0.77	-0.95	-0.89	0.13	-0.13
Retained Earnings	-0.52	0.15	0.36		-0.96	-0.81	-0.97	0.15	-0.51	-0.02	0.82	-0.84
Accounts Payable	0.33	-0.38	-0.19	-0.96		0.67	0.95	-0.38	0.31	-0.21	-0.92	0.93
Net Receivables	0.87	0.4	-0.81	-0.81	0.67		0.86	0.4	0.86	0.56	-0.5	0.51
Total Liab	0.6	-0.09	-0.49	-0.97	0.95	0.86		-0.09	0.59	0.1	-0.86	0.87
Net Invested Capital	0.74	1.0	-0.77	0.15	-0.38	0.4	-0.09		0.75	0.98	0.46	-0.47
Total Current Assets	1.0	0.75	-0.95	-0.51	0.31	0.86	0.59	0.75		0.86	-0.24	0.23
Net Working Capital	0.85	0.98	-0.89	-0.02	-0.21	0.56	0.1	0.98	0.86		0.29	-0.29
Common Stock	-0.25	0.46	0.13	0.82	-0.92	-0.5	-0.86	0.46	-0.24	0.29		-1.0
Short Term Debt	0.24	-0.47	-0.13	-0.84	0.93	0.51	0.87	-0.47	0.23	-0.29	-1.0

Click cells to compare fundamentals

About NeuroSense Therapeutics Financial Statements

NeuroSense Therapeutics investors use historical fundamental indicators, such as NeuroSense Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NeuroSense Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Gross Profit	-97 K	-92.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Additional Tools for NeuroSense Stock Analysis

When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC